الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 61 |  |  |
| | | from | 61 | | |
Abstract
Preeclampsia is a disease of vascular endothelial dysfunction and generalized maternal vasoconstriction that occurs after 20 weeks’ gestation and can manifest as late as 4-6 weeks postpartum. It is clinically defined by increase in blood pressure and proteinuria, with or without abnormal edema. Placental growth factor (PlGF) is a protein from the vascular endothelial growth factor (VEGF) family, which promotes angiogenesis. It is present in high concentrations in villous cytotrophoblast and syncytiotrophoblast tissue with levels increasing throughout pregnancy, with a peak of around 30–32 weeks of gestation, followed by a decrease, probably due to placental maturation.
The aim of the study was to assess serum level of placental growth factor in pregnant women with high risk of pre-eclampsia and evaluation of secondary outcomes included adverse maternal and perinatal outcomes in case of abnormally low levels of serum PlGF.
This study was a case series randomized study conducted on 250 pregnant females with high risk of preeclampsia attending antenatal care clinic in El-Shatby maternity university hospital. The Triage PlGF test is a single use, fluorescence immunoassay device, which is used with the CE-marked Triage Meter Pro point of care analyzer.
There was no clear association between patients’ age, BMI or history of medical disorders and the values of maternal serum PlGF, thus, this biomarker isn’t affected by predisposing risk factors of preeclamptic disorders.
There was no significant association between low maternal serum PlGF and blood pressure increase in the subsequent visits, 26 cases out of 140 cases (18.5%) with maternal serum PlGF value less than 100 pg/ml.
Results of studying the relation between developing intrauterine growth restriction (IUGR) among cases with low serum PlGF, there was significant association between the values of PlGF and abnormal fetal doppler US findings in patients with no significant increase in blood pressure during subsequent visits along the pregnancy as 19 out of 114 cases (16.7 %) with serum PlGF values (<100 pg/ml) developed abnormal fetal doppler ultrasound.
Maternal serum placental growth factor (PlGF) as a biomarker isn’t affected by features of high risk asymptomatic preeclamptic patients, its low levels had no significant relation with subsequent increase in the blood pressure, while, having significant association with IUGR and termination of pregnancy less than 35 weeks of gestation due to complications thus it can be a candidate for diagnostic and prognostic purposes